CbrigsFEM-2
MSGPPPPKTNEKSSQPVTG-RSQEPTRKGQLGPNYLRIIEEDEEYGHALLEPSEEQIKFE 59
CremFEM-2
----MSDSLNHPSSSTVHADDGFEPPTSP----------EDNNK------KPSLEQIKQE 40
CeleFEM-2
-----------------------------------------------------MEKVNEE 7
============================================================
humanPP2Calpha
------------------------------------------------------------ 0
CbrigsFEM-2
REALFEDLHLDRQRSARSFIEETFEEEMLGPQN-GIPPTTESPQSYIPIRYRNPPAAAPV 118
CremFEM-2
REALFTDLFADRRRSARSVIEEAFQNELMSAE--PVQPNVPNPHS-IPIRFRHQPVAGPA 97
CeleFEM-2
RDAVFEDHIGDRRRSVRSLLEEAFADEMEKTSYDVEVADTPQPH--IPIRFRHPPIAGPV 65
============================================================
humanPP2Calpha
------------------------------------------------------------ 0
CbrigsFEM-2
HDVFGDAVHAIFQKLMTRGPPVEYCHWMSYWIAKQID-KDSPVKYHECRFTPDQYVTENT 177
CremFEM-2
HDVFGDAVHSIFQKIMSRGVNADYSHWMSYWIALGID-KKTQMNYHMKPFCKDTYATEGS 156
CeleFEM-2
HDVFGDAIHDIFQKMMKRGQAVDFCHWVSHLIATEIDEKFSEVAFRDVQYNPDIYVTDST 125
============================================================
humanPP2Calpha
------------------------------------------------------------ 0
CbrigsFEM-2
AEAKKTYMDNMWKAAEKNLWMYTYNSPLLRTKWTGIHVSAEQIKGQRHKQEDRFVA-YPN 236
CremFEM-2
LEAKQTFTDKIRSAVEEIIWKSAEYCDILSEKWTGIHVSADQLKGQRNKQEDRFVA-YPN 215
CeleFEM-2
TEAKKLFNDKIWPAIDKILQQNAETCPILSEKWSGIHVSGDQLKGQRHKQEDRFLA-YPN 184
============================================================
humanPP2Calpha
--------------MGAFLDKPKMEKHNAQGQGNGLRYGLSSMQGWRVEMEDAHTAVIGL 46
CbrigsFEM-2
SLYMDTSRSDHIALLGVFDGHGGHECSQYAAGHMWETWIETRASHFEE------PLEKQL 290
CremFEM-2
GQYMNRGQSD-ISLLAVFDGHGGHECSQYAAAHFWEAWSDAQHHHSQDM-----KLDELL 269
CeleFEM-2
GQYMDRGEDP-ISVLAVFDGHGGHECSQYAAGHLWETWLEVRKSRDPSD-----SLEDQL 238
============================================================
humanPP2Calpha
PSGLES-----WSFFAVYDGHAGSQVAKYCCEHLLDHITNNQDFKGSAGAPSVENVKNGI 101
CbrigsFEM-2
KTSLDLLDERMTVRSTKE--CWKGGTTAVCCAIDMNKKELAFAWLGDSPGYIMDNLEVRK 348
CremFEM-2
EKALETLDERMTVRSVRE--SWKGGTTAVCCAVDLNTNQIAFAWLGDSPGYIMSNLEFRK 327
CeleFEM-2
RKSLELLDERMTVRSVKE--CWKGGSTAVCCAIDMDQKLMALAWLGDSPGYVMSNIEFRQ 296
============================================================
humanPP2Calpha
RTGFLEIDEHMRVMSEKKHGADRSGSTAV--GVLISPQHTYFINCGDSRGLLCRNRKVHF 159
CbrigsFEM-2
VTRDHSPSDPEEGRRVEEAGGQLFVIGGELRVNGVLNLTRALGDV---------PGRPMI 399
CremFEM-2
FTTEHSPSDPEECRRVEEVGGQIFVIGGELRVNGVLNLTRALGDV---------PGRPMI 378
CeleFEM-2
LTRGHSPSDEREARRVEEAGGQLFVIGGELRVNGVLNLTRALGDV---------PGRPMI 347
============================================================
humanPP2Calpha
FTQDHKPSNPLEKERIQNAGGSVMI----QRVNGSLAVSRALGDFDYKCVHGKGPTEQLV 215
CbrigsFEM-2
SNQAETCQRDIEVG---DYLVILACDGISDVFNTSDLYNLVQAYVNENPVEEYNDLAHYI 456
CremFEM-2
SNKPDTLLKTIEPA---DYLVLLACDGISDVFNTSDLYNLVQAFVNEYDVEDYHELARYI 435
CeleFEM-2
SNEPETCQVPIESS---DYLVLLACDGISDVFNERDLYQLVEAFANDYPVEDYAELSRFI 404
============================================================
humanPP2Calpha
S--PEPEVHDIERSEEDDQFIILACDGIWDVMGNEELCDFVRSRLE--VTDDLEKVCNEV 271
CbrigsFEM-2
CHEAIAHGSTDNVTVV-IGFLRPPQDLWRMMKIDEESDEEEDEVDDE------------- 502
CremFEM-2
CNQAVSAGSADNVTVV-IGFLRPPEDVWRVMK--TDSDDEESELEEEDDNE--------- 483
CeleFEM-2
CTKAIEAGSADNVSVV-IGFLRPPQDVWKLMK--HESDDEDSDVTDEE------------ 449
============================================================
humanPP2Calpha
VDTCLYKGSRDNMSVILICFPNAPKVSPEAVK--KEAELDKYLECRVEEIIKKQGEGVPD 329
CbrigsFEM-2
----------------------------------------------------- 502
CremFEM-2
----------------------------------------------------- 483
CeleFEM-2
----------------------------------------------------- 449
=====================================================
humanPP2Calpha
LVHVMRTLASENIPSLPPGGELASKRNVIEAVYNRLNPYKNDDTDSTSTDDMW 382
-
Two views of a molecule and a reference alignment colored using COMBOSA.
Residues that are identical among the aligned sequences that were used
are colored dark blue, while similar residues are colored light blue. Residues
that are not identical or similar among the aligned sequences are colored
red. Residues missing from the aligned sequences (due to deletions relative
to the solved sequence) are colored gray. The reference alignment shows
how the coloring is applied from the sequences being compared to the molecule
of known structure.
Back Home